Caveolin‐1 overexpression is associated with aggressive prostate cancer recurrence
- 13 February 2007
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 67 (6) , 614-622
Abstract
Background: Caveolin‐1 protein suppresses apoptotic cell death in prostate cancer. The objectives of this study were to investigate the association of Caveolin‐1 expression with established features of prostate cancer as well as overall and aggressive disease recurrence in patients treated with radical prostatectomy (RP).Methods: Caveolin‐1 immunostaining was performed on a tissue microarray containing prostatectomy specimen cores from 232 consecutive patients treated with RP for clinically localized prostatic adenocarcinoma. Caveolin‐1 over‐expression was defined as more than 50% of cells staining positively for Caveolin‐1. Patients were categorized as having features of aggressive disease recurrence if they had a positive metastatic work‐up, post‐recurrence PSA doubling time less than 10 months, and/or failure to respond to local salvage radiation therapy.Results: Seventy patients (30.2%) exhibited over‐expression of Caveolin‐1. Caveolin‐1 over‐expression was associated with higher pathologic Gleason sum (P = 0.038) and higher pre‐operative PSA level (P = 0.024). Patients with Caveolin‐1 over‐expression were at increased risk of PSA recurrence after surgery (P = 0.023) in univariate but not in standard post‐operative multivariate analysis. However, patients with Caveolin‐1 over‐expression were at increased risk of aggressive prostate cancer recurrence in both univariate and multivariate analysis (P < 0.001 and P = 0.001, respectively).Conclusions: Over‐expression of Caveolin‐1 was associated with established features of prostate cancer and aggressive PSA recurrence. Caveolin‐1 might help identify patients at high risk of developing aggressive prostate cancer recurrence, thus allowing selection of patients who might benefit from early systemic therapeutic intervention. Prostate 67: 614–622, 2007.Keywords
This publication has 29 references indexed in Scilit:
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Caveolin-1 in oncogenic transformation, cancer, and metastasisAmerican Journal of Physiology-Cell Physiology, 2005
- CANCER PROGRESSION AND SURVIVAL RATES FOLLOWING ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY IN 3,478 CONSECUTIVE PATIENTS: LONG-TERM RESULTSJournal of Urology, 2004
- Caveolae: From Cell Biology to Animal PhysiologyPharmacological Reviews, 2002
- CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTSJournal of Urology, 2002
- Loss of Caveolae, Vascular Dysfunction, and Pulmonary Defects in Caveolin-1 Gene-Disrupted MiceScience, 2001
- LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMYUrologic Clinics of North America, 2001
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999
- Genes encoding human caveolin‐1 and ‐2 are co‐localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancersFEBS Letters, 1998
- Expression and Characterization of Recombinant CaveolinJournal of Biological Chemistry, 1996